Yunnan Biovalley Pharmaceutical Co (BJSE:833266) Long-Term Capital Lease Obligation : ¥0.6 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Yunnan Biovalley Pharmaceutical Co Long-Term Capital Lease Obligation?

Yunnan Biovalley Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥0.6 Mil.

Yunnan Biovalley Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 (¥0.8 Mil) to Dec. 2024 (¥0.5 Mil) but then increased from Dec. 2024 (¥0.5 Mil) to Mar. 2025 (¥0.6 Mil).

Yunnan Biovalley Pharmaceutical Co's annual Long-Term Capital Lease Obligation increased from Dec. 2022 (¥1.2 Mil) to Dec. 2023 (¥1.4 Mil) but then declined from Dec. 2023 (¥1.4 Mil) to Dec. 2024 (¥0.5 Mil).

Yunnan Biovalley Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Yunnan Biovalley Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yunnan Biovalley Pharmaceutical Co Long-Term Capital Lease Obligation Chart

Yunnan Biovalley Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

15.68

1.79

1.17

1.36

0.46

Yunnan Biovalley Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.19	0.63	0.82	0.46	0.64

Yunnan Biovalley Pharmaceutical Co (BJSE:833266) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Yunnan Biovalley Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Yunnan Biovalley Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Yunnan Biovalley Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yunnan Biovalley Pharmaceutical Co Ltd (BJSE:833266) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

No. 999 Biological Valley Street, Majinpu New District, High-tech Zone, Yunnan Province, Kunming City, CHN, 650500

Website

http://ynswgen.biovalley.cn

Yunnan Biovalley Pharmaceutical Co Ltd engages in research and development, production, and marketing of pharmaceuticals and health care based on herbal medicines. The products on the market include breviscapine injection, breviscapine Shengmai capsules, breviscapine tablets, breviscapine dripping pills, Erigeron Capsules, Erigeron Soft Capsules.

Yunnan Biovalley Pharmaceutical Co Headlines

No Headlines